---

Cervical Cancer - Detailed Point-Wise Overview

---

1. EPIDEMIOLOGY

• Third most common gynecologic cancer in the United States; globally, it is the 4th most common cancer in women
• Over 14,000 new cases and >4,000 deaths annually in the US
• A >80% decrease in incidence since the 1950s in developed countries, largely due to Pap test screening and now HPV testing
• Remains a leading cause of cancer death in women in Central/South America and sub-Saharan Africa due to lack of screening access
• In low- and middle-income countries, age-standardized mortality rate = 12.4 per 100,000 vs. 5.2 per 100,000 in high-income countries
• Disproportionately affects women of lower socioeconomic status, Hispanic and Black American women, and those in minority ethnic groups
• Median age at diagnosis: 48 years
• At diagnosis by stage: ~38% stage I, 32% stage II, 26% stage III, 4% stage IV

---

2. ETIOLOGY AND RISK FACTORS

• HPV infection detected in >99% of cervical cancers - it is the necessary (though not sufficient) cause
• Of >200 HPV strains, ~40 infect the genital tract:
  • Low-risk HPV (6, 11): genital warts
  • High-risk HPV (oncogenic): cervical, vaginal, vulvar, anal, penile, oropharyngeal cancers
  • HPV 16 and 18 cause 70% of cervical cancers
  • HPV types 31, 33, 45, 52, 58 account for an additional 20%
• HPV transmitted via genital-genital or genital-oral contact; most sexually active individuals acquire HPV, usually early in sexual activity
• Risk factors (Goldman-Cecil Table 184-1):
  • Early onset of sexual activity
  • Multiple sexual partners
  • History of genital warts
  • Multiparity
  • Lower socioeconomic status
  • Cigarette smoking
  • Long-term oral contraceptive use (RR ~1.9 with ≥5 years)
  • HIV infection and other immunodeficiency states
  • In utero diethylstilbestrol (DES) exposure
  • IUD use is protective (associated with ~1/3 reduction in risk)

---

3. PATHOBIOLOGY / MOLECULAR MECHANISMS

• HPV: small, nonenveloped double-stranded DNA virus; capsid formed by late proteins L1 and L2
• HPV infects the basal cell layer of stratified squamous epithelium at the squamocolumnar junction (transformation zone)
• Key oncoproteins: E6 and E7
  • E6 binds and degrades p53 tumor suppressor → inhibits apoptosis → cell immortalization
  • E7 binds and degrades pRB tumor suppressor → dysregulates cyclins and CDKs → uncontrolled cell cycle progression
  • Both E6 and E7 have immunosuppressive effects → immune evasion, peripheral T-cell tolerance
• HPV can exist as:
  • Episome (extrachromosomal) - usually in early/low-grade disease
  • Integrated into host DNA - associated with malignant transformation
• Most HPV infections (~90%) are transient and self-clearing within 1-2 years
• ~10% of women develop persistent infection → required for progression to cancer
• The carcinogenic process takes approximately a decade to develop into malignancy
• Squamocolumnar junction susceptibility is highest in adolescents/young women; declines with hormonal maturation
• Additional mutations accumulating during increased cellular proliferation also contribute to malignant transformation

---

4. PRECURSOR LESIONS (CIN / SIL)

• HPV-related carcinogenesis begins with Squamous Intraepithelial Lesion (SIL) - usually precedes invasive cancer by years to decades
• SIL peaks at ~30 years; invasive carcinoma peaks at ~45 years

Classification Systems

Natural History of SIL (Robbins)

• LSIL: high viral replication, mild host cell alteration - NOT premalignant
• HSIL: increased proliferation, arrested maturation, lower viral replication - premalignant; ~20% develop de novo (without prior LSIL)
• Risk factors for LSIL → HSIL progression: cigarette smoking, immunocompromise
• Both SIL grades are asymptomatic; detected only via Pap smear + colposcopy

---

5. HISTOLOGIC TYPES OF INVASIVE CARCINOMA

• Squamous cell carcinoma: ~80% - most common; peaks at ~45 years
• Adenocarcinoma and adenosquamous carcinoma: ~15% - incidence increasing in developed countries; harder to detect by Pap smear
• Small cell neuroendocrine carcinoma: <5% - very poor prognosis, resembles small cell lung cancer morphologically
• Gastric-type adenocarcinoma: HPV-independent, also very poor prognosis

Morphology of Invasive SCC

• Develops in the transformation zone
• Ranges from microscopic stromal invasion to grossly exophytic tumors
• Tongues and nests of squamous cells with desmoplastic stromal response
• Grading by degree of differentiation; well-differentiated = keratin pearls
• "Barrel cervix": tumor encircling cervix and invading stroma
• Risk of lymph node metastasis correlates with depth of invasion and lymphovascular space invasion (LVSI)

---

6. PATTERNS OF SPREAD

• Local extension (most common): uterine corpus, vagina, bladder, parametria, rectum
• Lymphatic spread: pelvic lymph nodes → para-aortic nodes
• Hematogenous spread (less common, advanced disease): lungs, liver, bone
• Most patients with advanced disease die from local invasion complications: ureteral obstruction, pyelonephritis, uremia - rather than distant metastases

---

7. CLINICAL FEATURES

• Early-stage: largely asymptomatic - detected via screening
• Symptomatic presentations (more advanced disease):
  • Postcoital bleeding (classic symptom)
  • Irregular or heavy vaginal bleeding
  • Abnormal vaginal discharge (watery, mucoid, or bloody)
  • Pelvic pain
  • Dyspareunia
• Advanced disease:
  • Bladder/bowel dysfunction
  • Lower extremity edema (lymphatic obstruction)
  • Flank pain (hydronephrosis)
  • Ureteral obstruction

---

8. DIAGNOSIS

• Pap smear (cervical cytology): screening tool; not adequate alone for diagnostic purposes in obvious lesions
• HPV DNA testing: higher sensitivity, lower specificity vs. Pap test; most useful in women ≥30 years
• Colposcopy: magnified visualization after acetic acid application; highlights abnormal epithelium as acetowhite areas
• Cervical biopsy: confirmatory diagnosis
• Cone biopsy / LEEP: excisional diagnosis and treatment for precancerous lesions
• Endocervical curettage: for endocervical lesions
• For obvious lesions: biopsy directly - do NOT rely on Pap smear

Workup for Staging

• Pelvic and rectovaginal examination
• Examination under anesthesia (EUA)
• Cystoscopy and proctoscopy (to assess bladder and rectal invasion)
• Imaging:
  • MRI: best for local staging, parametrial involvement (superior sensitivity vs. CT on T2-weighted imaging)
  • CT: excellent specificity (97%), used for nodal/metastatic disease
  • PET/CT: superior sensitivity + specificity for lymph node metastases vs. CT or MRI alone; best for detecting extrapelvic disease
  • PET sensitivity (75%), specificity (98%) > CT (58%, 92%) > MRI (56%, 93%) for lymph nodes

---

9. FIGO STAGING (2018 REVISED)

• Stage IA: horizontal spread no longer considered; only depth matters
• Stage IB: now 3 substages (IB1/2/3)
• Stage IIIC added: lymph node metastasis now upstages regardless of tumor size
• Imaging and pathology can supplement clinical staging in all stages
• If doubt between stages, assign the lower stage

---

10. TREATMENT BY STAGE

Stage IA1 (microscopic, <3 mm)

• Cone biopsy / LEEP: sufficient if surgical margins clear and LVSI absent
• Simple hysterectomy if childbearing complete

Stage IA2 - IB1

• Radical hysterectomy (Wertheim) with pelvic lymphadenectomy OR
• Definitive radiation therapy (equally effective)
• Fertility-sparing: radical trachelectomy (removal of cervix only) in select cases with IB1 (<2 cm)
• Open surgery is standard - minimally invasive (laparoscopic/robotic) associated with worse disease-free survival (especially if tumor >2 cm)

Stage IB2 - IIA

• Radical hysterectomy + lymphadenectomy, OR
• Concurrent chemoradiation (CCRT)

Stage IB3 - IVA (locally advanced)

• Definitive chemoradiation is the standard of care:
  • External beam radiation therapy (EBRT) to pelvis
  • Concurrent weekly cisplatin (radiosensitizer)
  • Followed by brachytherapy (intracavitary/interstitial)
• Surgical resection not preferred for tumors >4 cm or pelvic sidewall extension

Adjuvant therapy after radical hysterectomy - indicated when:

• Positive surgical margins
• Parametrial involvement
• Lymph node metastasis
• Deep stromal invasion
• Large tumor size
• Lymphovascular space invasion (LVSI)

Advanced/Recurrent/Metastatic (Stage IVB)

• Systemic chemotherapy: platinum-taxane doublet (cisplatin/paclitaxel or carboplatin/paclitaxel)
• Bevacizumab (anti-VEGF antibody): adds incremental survival benefit when combined with chemotherapy
• Pembrolizumab (PD-1 inhibitor): combined with chemotherapy ± bevacizumab for PD-L1 expressing tumors (KEYNOTE-826 data)
• Pelvic exenteration (anterior/posterior/total): for central recurrence in selected patients; cures 25-50%, but highly morbid

---

11. PROGNOSIS / 5-YEAR SURVIVAL

• Prognosis worsens with neuroendocrine histology and gastric-type adenocarcinoma
• Survival is significantly better when managed by a gynecologic oncologist

---

12. SCREENING (2025/2026 UPDATED GUIDELINES)

• Cervical cytology alone (Pap smear):
  • Start at age 21
  • Ages 21-29: Pap smear every 3 years
  • Age <30: HPV testing alone NOT recommended (high prevalence of transient infection, low positive predictive value)
• Co-testing (Pap + HPV) or primary hrHPV testing alone:
  • Ages 30-65: primary HPV testing every 5 years (preferred) OR Pap every 3 years
• Self-collected hrHPV testing (2025-2026 ACOG/ACS update):
  • Now an acceptable and endorsed option for average-risk women aged 30-65
  • Self-collected vaginal specimens for hrHPV every 3 years
  • Aims to expand access, especially in underserved communities
• Exit from screening: after age 65 with two documented negative hrHPV tests (the last at age 60 and 65) - ACS 2025 guideline
• Abnormal Pap/HPV → colposcopy → biopsy → management per ASCCP guidelines
• Women with HIV, immunocompromise, or DES exposure require more frequent screening

---

13. PREVENTION

HPV Vaccination

• 9-valent HPV vaccine (Gardasil 9): covers types 6, 11, 16, 18, 31, 33, 45, 52, 58
• Recommended for boys and girls at 11-12 years (can begin at age 9)
• Catch-up vaccination for all persons through age 26
• Shared decision-making for ages 27-45
• Males must be vaccinated: reduce transmission to women, and prevent HPV-related anal/oropharyngeal cancers in men
• Vaccines do NOT supplant continued screening (protection against most but not all oncogenic HPV types)
• WHO 90-70-90 target: vaccinate 90% of girls by age 15, screen 70% of women aged 35-45 twice in a lifetime, treat 90% of HSIL/invasive cancers - projected to reduce incidence to <4/100,000

Other Preventive Measures

• Barrier contraception (condoms) reduces HPV transmission
• Avoid smoking
• Limit number of sexual partners
• Regular screening for early detection and treatment of precancerous lesions

---

14. SPECIAL SURGICAL PROCEDURES

• LEEP (Loop Electrosurgical Excision Procedure): office procedure; wire loop heated by electrical current excises transformation zone with CIN - both diagnostic and therapeutic
• Cold Knife Conization (CKC): OR procedure; wider excision, used for higher-grade lesions or when LEEP margins unclear
• Radical hysterectomy (Wertheim): removes uterus, upper vagina, parametria, and pelvic lymph nodes; open approach is standard
• Radical trachelectomy: fertility-sparing; removes cervix + parametria while preserving the uterine body; for early-stage (<2 cm, IB1)
• Pelvic exenteration: removal of bladder, uterus, vagina, rectum in cases of central pelvic recurrence

---

• Goldman-Cecil Medicine International Edition, Ch. 184
• Berek & Novak's Gynecology, Ch. 38
• Robbins & Cotran Pathologic Basis of Disease, Ch. 22
• Robbins & Kumar Basic Pathology, Ch. 17
• Sabiston Textbook of Surgery, Ch. 120
• ACOG Committee Statement 28, April 2026
• ACS 2025 Cervical Cancer Screening Guideline Update

---

🧬 NEET PG MCQ Quiz — Cell Injury (Part 1)

Based on your uploaded notes + Robbins Pathology

---

SECTION A: BASICS OF CELL INJURY

---

• A) Radiation
• B) Chemical toxins
• C) Hypoxia ✅
• D) Immunologic injury

Explanation: Hypoxia (oxygen deficiency) is the most common and clinically important cause of cell injury. It impairs oxidative phosphorylation, leading to ATP depletion.

---

• A) Anemia
• B) Carbon monoxide poisoning
• C) Respiratory failure
• D) Ischemia ✅

Explanation: Ischemia (interrupted blood supply) is the most common cause of hypoxia. It not only reduces oxygen delivery but also stops removal of metabolic waste products, making it more damaging than hypoxia alone.

---

• A) Fibroblast
• B) Hepatocyte
• C) Neuron (Brain cells) ✅
• D) Cardiomyocyte

Explanation: Neurons are the most sensitive to hypoxia - they begin to die within 3-5 minutes of ischemia. They have high metabolic demands and cannot undergo anaerobic glycolysis effectively.

---

• A) Neuron
• B) Cardiomyocyte
• C) Renal tubular cell
• D) Fibroblast ✅

Explanation: Fibroblasts are the most resistant cells to hypoxia. They have low metabolic demands and can survive prolonged oxygen deprivation.

---

• A) Irreversible injury → Reversible injury → Cell death
• B) Reversible injury → Cell death → Irreversible injury
• C) Adaptation fails → Reversible injury → Irreversible injury → Cell death ✅
• D) Adaptation fails → Cell death → Reversible injury

Explanation: The progression is: Normal cell → Stress/Injury → Adaptation (if adequate) → OR if adaptation fails → Reversible injury → (if injury continues) → Irreversible injury → Cell death.

---

SECTION B: REVERSIBLE CELL INJURY

---

• A) Nuclear pyknosis
• B) Plasma membrane rupture
• C) Formation of myelin figures
• D) Mitochondrial dysfunction with decreased ATP production ✅

Explanation: The very first change is mitochondrial dysfunction leading to decreased ATP production. This initiates a cascade including Na-K ATPase pump failure and cellular swelling.

---

• A) Nuclear fragmentation
• B) Myelin figure formation
• C) Cellular swelling / Hydropic change ✅
• D) Fatty change

Explanation: Cellular swelling (hydropic change) is the first morphological change visible on microscopy. It results from Na-K ATPase pump failure causing Na⁺ and water influx.

---

• A) Cellular swelling
• B) Water influx into the cell
• C) ER swelling
• D) Increased protein synthesis ✅

Explanation: Na-K ATPase failure causes: Na⁺ influx → water influx → cellular swelling, ER swelling, flattening of microvilli, and cytoplasmic bleb formation. Protein synthesis is actually DECREASED (due to ribosome detachment from ER).

---

• A) Cellular swelling
• B) ER swelling
• C) Cytoplasmic bleb formation
• D) Plasma membrane rupture ✅

Explanation: Plasma membrane rupture is a feature of IRREVERSIBLE cell injury. In reversible injury the membrane is intact (though blebs form). Key features of reversible injury: cellular swelling, ER dilation, microvilli loss, bleb formation, myelin figures, fatty change.

---

• A) Increased mitochondrial activity
• B) Nuclear fragmentation
• C) Decreased protein synthesis → Fatty change ✅
• D) Increased glycolysis

Explanation: Ribosome detachment (during ATP depletion) causes decreased protein synthesis. Decreased apoprotein synthesis impairs fat export from hepatocytes → fatty change (steatosis).

---

• A) Are seen only in irreversible injury
• B) Are composed mainly of proteins
• C) Are derived from the nucleus
• D) Are seen in both reversible and irreversible injury, more in irreversible ✅

Explanation: Myelin figures are derived from cell membranes and are composed primarily of phospholipids (+ Ca²⁺). They are seen in both reversible and irreversible injury but are more prominent in irreversible injury.

---

• A) Proteins and cholesterol
• B) Nucleic acids and lipids
• C) Phospholipids (primarily) and Ca²⁺ ✅
• D) Glycoproteins

Explanation: Myelin figures (concentric lamellation) are derived from damaged cell membranes and are composed primarily of phospholipids with some calcium.

---

SECTION C: IRREVERSIBLE CELL INJURY

---

• A) Cellular swelling and nuclear pyknosis
• B) Fatty change and myelin figures
• C) Severe mitochondrial damage + Massive Ca²⁺ influx into the cell ✅
• D) Ribosome detachment and ER dilation

Explanation: The two hallmarks of irreversible cell injury are: (1) Severe mitochondrial vacuolization/damage (loss of oxidative phosphorylation) and (2) Massive Ca²⁺ influx, which activates destructive enzymes.

---

• A) Kinases, Ligases, Isomerases
• B) Oxidases, Reductases, Transferases
• C) Phospholipase, Protease, Nuclease ✅
• D) ATPases, Lipases, Synthases

Explanation: Ca²⁺ activates three key destructive enzymes:

• Phospholipase → membrane damage
• Protease → cytoskeletal/structural protein breakdown
• Nuclease → DNA fragmentation

---

• A) Karyorrhexis → Pyknosis → Karyolysis
• B) Karyolysis → Karyorrhexis → Pyknosis
• C) Pyknosis → Karyorrhexis → Karyolysis ✅
• D) Karyolysis → Pyknosis → Karyorrhexis

Explanation:

• Pyknosis: nuclear shrinkage + chromatin condensation (dark, small nucleus)
• Karyorrhexis: nuclear fragmentation
• Karyolysis: nuclear dissolution (fading/disappearance of nucleus)

---

• A) Nuclear fragmentation
• B) Nuclear dissolution
• C) Nuclear enlargement with pale staining
• D) Nuclear shrinkage with chromatin condensation (small, dark nucleus) ✅

Explanation: Pyknosis = the nucleus becomes small and dark due to chromatin condensation. It is the first nuclear change in cell death.

---

• A) Chromatin condensation
• B) Nuclear dissolution/fading
• C) Nuclear fragmentation ✅
• D) Nuclear swelling

Explanation: Karyorrhexis means nuclear fragmentation - the condensed nucleus breaks apart into fragments.

---

• A) Increases (becomes alkaline)
• B) Remains unchanged
• C) Decreases (becomes acidic) ✅
• D) Fluctuates randomly

Explanation: Anaerobic glycolysis produces lactic acid → H⁺ accumulation → acidic pH. This acidic pH causes nuclear chromatin to clump.

---

SECTION D: NECROSIS

---

• A) Programmed physiological cell death without inflammation
• B) Cell death due to radiation only
• C) Pathological cell death associated with inflammation ✅
• D) Cell death mediated by caspase activation

Explanation: Necrosis = pathological cell death with inflammation. Cellular membranes are destroyed, enzymes leak out, and local inflammation is triggered to clear the debris. This distinguishes it from apoptosis.

---

• A) Basophilic (blue)
• B) Pale/clear
• C) Eosinophilic (pink) ✅
• D) Deeply basophilic

Explanation: Necrotic cells appear eosinophilic (pink) on H&E staining due to: (1) decreased cytoplasmic RNA (RNA stains blue), and (2) denatured cytoplasmic proteins (which bind eosin/pink stain more).

---

• A) Caseous necrosis
• B) Liquefactive necrosis
• C) Fat necrosis
• D) Coagulative necrosis ✅

Explanation: Coagulative necrosis is the most commonly occurring type of necrosis. It occurs in solid organs (heart, kidney, liver) following ischemia/infarction.

---

• A) Enzymatic liquefaction of tissue
• B) Caseation with loss of architecture
• C) Protein denaturation with preservation of tissue architecture ✅
• D) Saponification of fat

Explanation: Coagulative necrosis = denaturation of proteins (structural + enzymatic). The key feature is that the tissue architecture (cell outlines/"tombstones") is PRESERVED even after cell death - the "ghost" cells remain.

---

• A) Nuclear fragmentation pattern
• B) Loss of all cellular detail
• C) Preservation of cell outlines without nuclear detail (ghost cells) ✅
• D) Chalky white deposits in tissue

Explanation: In coagulative necrosis, dead cells retain their outlines ("ghost cells" or "tombstone appearance") because proteins are denatured but cell shapes are maintained. This is also seen in Proteus vulgaris infection.

---

• A) Round
• B) Irregular
• C) Rhomboid
• D) Wedge-shaped ✅

Explanation: Infarcts (coagulative necrosis) in solid organs appear wedge-shaped because the vessels supplying them are end-arteries arranged in a cone/fan shape with the apex pointing toward the occluded vessel.

---

• A) Heart
• B) Kidney
• C) Liver
• D) Brain / CNS ✅

Explanation: The brain undergoes liquefactive necrosis (also called colliquative necrosis) because brain tissue has abundant lipids and little structural protein. Enzymatic digestion dominates over protein denaturation, converting the tissue to liquid.

---

• A) Fat necrosis in pancreas
• B) Brain infarction
• C) Tuberculosis (and some fungi like Histoplasma, Coccidioides) ✅
• D) Malignant hypertension

Explanation: Caseous necrosis (cheese-like gross appearance, loss of all architecture microscopically) is the hallmark of tuberculosis. It also occurs in fungal infections like Histoplasmosis and Coccidioidomycosis.

---

• A) Red-brown hemorrhagic areas
• B) Yellow-white caseous material
• C) Chalky white deposits (Ca²⁺ saponification) ✅
• D) Clear fluid-filled cavities

Explanation: Fat necrosis (in pancreas/peripancreatic fat) involves lipase-mediated breakdown of triglycerides → free fatty acids + glycerol. Free fatty acids combine with Ca²⁺ → calcium soaps (saponification) → chalky white deposits.

---

• A) Polyarteritis Nodosa (PAN)
• B) Rheumatic Heart Disease (Aschoff bodies)
• C) Malignant Hypertension
• D) Tuberculosis ✅

Explanation: Fibrinoid necrosis is seen in: PAN, Rheumatic Heart Disease (Aschoff bodies), SLE, Malignant Hypertension. Tuberculosis causes CASEOUS necrosis. Fibrinoid necrosis = immune complex deposition + fibrin deposition in vessel walls, giving a bright pink "fibrin-like" appearance.

---

• A) SLE
• B) Polyarteritis Nodosa
• C) Malignant Hypertension
• D) Rheumatic Heart Disease ✅

Explanation: Aschoff bodies are pathognomonic of Rheumatic Heart Disease (RHD). They are foci of fibrinoid necrosis surrounded by Anitschkow cells (caterpillar cells) and Aschoff giant cells.

---

• A) Coagulative necrosis with a line of demarcation
• B) Purely ischemic in origin
• C) Liquefactive necrosis + infection WITHOUT a line of demarcation ✅
• D) Associated with arterial occlusion only

Explanation:

• Dry gangrene = Coagulative necrosis (ischemia) WITH a clear line of demarcation; no infection
• Wet gangrene = Liquefactive necrosis + bacterial infection; NO line of demarcation; more dangerous (systemic spread)

---

QUICK REVISION TABLE

---

• 28-30 correct: Excellent - NEET PG ready
• 23-27 correct: Good - revise weak areas
• 18-22 correct: Average - need focused revision
• <18 correct: Revise the full topic